SEC Filing Summary: Trovagene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on August 14, 2013. The filing serves to announce the company's financial results for the second quarter ended June 30, 2013. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, CA.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued via a press release, which is attached as Exhibit 99.1, but the text of the press release is not included in the source data.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of the Q2 2013 results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 unless specifically incorporated by reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K text.
- Confirm the company name discrepancy: The metadata lists "Cardiff Oncology, Inc.", but the filing is for "Trovagene, Inc." (Note: Trovagene was later acquired by Cardiff Oncology).
- Review the full press release for any operational updates or clinical trial milestones associated with the Q2 2013 period.